Cart
sales@molnova.com
AJ2-30
CAS No. 2700322-79-6
AJ2-30( —— )
Catalog No. M37014 CAS No. 2700322-79-6
AJ2-30 is an SLCl5A4 inhibitor that inhibits TLR9-mediated B cell activation and inhibits MDP transporter.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 117 | In Stock |
|
| 5MG | 103 | In Stock |
|
| 10MG | 170 | In Stock |
|
| 25MG | 353 | In Stock |
|
| 50MG | 554 | In Stock |
|
| 100MG | 788 | In Stock |
|
| 200MG | 1051 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAJ2-30
-
NoteResearch use only, not for human use.
-
Brief DescriptionAJ2-30 is an SLCl5A4 inhibitor that inhibits TLR9-mediated B cell activation and inhibits MDP transporter.
-
DescriptionAJ2-30 is a SLCl5A4 inhibitor. AJ2-30 inhibits TLR9-mediated B cell activation. AJ2-30 block endogenous NOD signaling in human and mouse macrophages. AJ2-30 can be used for research of inflammation.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2700322-79-6
-
Formula Weight354.45
-
Molecular FormulaC23H22N4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (141.06 mM; Ultrasonic (<60°C)
-
SMILESN=1C=2C=CC=CC2N(C1NCC3=CC=C4C(=C3)C=5C=CC=CC5N4CC)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Daniel Lazar, et al. Small molecule inhibitors of scl15a4 with anti-inflammatory activity. Patent. WO2021174023.
molnova catalog
related products
-
Rituximab
Rituximab anti-CD20) is a chimeric anti-CD20 mAb that binds the CD20 antigen on B cells with a binding affinity of 5 nM.
-
TAT-amide
TAT-amide is a cell penetrating peptide. Cell-penetrating peptides (CPPs) are short amino acid sequences able to enter different cells.
-
Lithium acetoacetate
Acetoacetic acid (AcAc) is a weak organic acid that can be produced in the human liver under certain conditions of poor metabolism leading to excessive fatty acid breakdown (diabetes mellitus leading to diabetic ketoacidosis).
